Enjaymo

Generic name: Sutimlimab-jome
Dosage form: injection, for intravenous use
Drug class: Selective immunosuppressants

Usage of Enjaymo

Enjaymo is a prescription medicine used to decrease the need for red blood cell transfusion due to the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if this medicine is safe and effective in children.

Enjaymo side effects

Enjaymo can cause serious side effects, including:

See information important.

Infusion-related reactions. Treatment with Enjaymo may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your infusion if you have an infusion-related reaction, and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your infusion that may mean you are having an infusion-related reaction, including:

shortness of breath

rapid heartbeat

nausea

flushing

headache

Risk of autoimmune disease. Enjaymo may increase your risk for developing an autoimmune disease such as SLE. Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including:

joint pain or swelling

rash on the cheeks and nose

unexplained fever

The most common side effects include:

respiratory tract infection

viral infection

diarrhea

indigestion

cough

joint pain

joint inflammation (arthritis)

swelling of the lower legs, ankles, and feet

These are not all the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before taking Enjaymo

Do not receive Enjaymo if you are allergic to sutimlimab-jome or any of the ingredients. See the end of this page for a complete list of ingredients.

Relate drugs

How to use Enjaymo

- For patients weighing 39 kg to less than 75 kg: 6,500 mg by intravenous infusion weekly for two weeks then every two weeks. - For patients weighing 75 kg or more: 7,500 mg by intravenous infusion weekly for two weeks then every two weeks.

Use: to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD).

Warnings

Enjaymo can cause serious side effects, including:

Serious infections. Enjaymo is a prescription medicine that affects your immune system. Enjaymo can lower the ability of your immune system to fight infections. People who take Enjaymo may have an increased risk of getting infections caused by certain kinds of bacteria such as Neisseria meningitides, Streptococcus pneumoniae, and Haemophilus influenzae. These infections may be serious or life-threatening. Some infections may quickly become lifethreatening or cause death if not recognized and treated early.

You need to receive vaccinations against infections caused by certain kinds of bacteria at least 2 weeks before your first dose of Enjaymo. You may need to have additional vaccinations during treatment.

If your healthcare provider decides that urgent treatment with Enjaymo is needed, you should receive vaccinations as soon as possible.

Vaccinations may reduce the risk of these infections, but do not prevent all infections. Call your healthcare provider or get medical help right away if you get any new signs and symptoms of an infection, including:

fever

severe headache with stiff neck or back

pain during urination or urinating more often than usual

cough or difficulty breathing

flu-like symptoms

pain, redness or swelling of the skin

See Enjaymo side effects.

What other drugs will affect Enjaymo

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.